news
Amgen’s Phase 3 Aranesp trial in MDS meets primary endpoint
16 February 2016 | By Victoria White
Aranesp reduced the incidence of red blood cell transfusions in anaemic patients with low and intermediate-1 risk myelodysplastic syndrome...
List view / Grid view
Amgen
news
Amgen’s Kyprolis launches in the UK for relapsed multiple myeloma
12 February 2016 | By Victoria White
Kyprolis (carfilzomib) is the first licensed irreversible proteasome inhibitor for use in combination treatment of patients with relapsed multiple myeloma...
news
Positive topline results from GAUSS-3 trial of Repatha
5 February 2016 | By Victoria White
The Phase 3 GAUSS-3 trial evaluating Amgen’s Repatha (evolocumab) in patients with high cholesterol who cannot tolerate statins met its co-primary endpoints...
news
Phase 3 study of Blincyto in ALL meets primary endpoint
5 February 2016 | By Victoria White
Blincyto is a BiTE antibody construct that binds specifically to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T cells...
news
FDA accepts BLA for Amgen’s Humira biosimilar, ABP 501
26 January 2016 | By Victoria White
Humira (adalimumab) is an anti-TNF-α monoclonal antibody which is approved in many regions for the treatment of several inflammatory diseases...
news
Vectibix and best supportive care improves OS in mCRC
25 January 2016 | By Victoria White
Amgen has announced results from a study of Vectibix and best supportive care in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC)...
news
FDA approves new Kyprolis combination therapy in multiple myeloma
22 January 2016 | By Victoria White
The FDA has approved the supplemental New Drug Application (sNDA) of Amgen’s Kyprolis (carfilzomib) for injection in combination with dexamethasone or with lenalidomide plus dexamethasone...
news
EC approves Imlygic as Europe’s first oncolytic immunotherapy
18 December 2015 | By Victoria White
The European Commission has approved the use of Amgen’s Imlygic (talimogen laherparepvec) for the treatment of adults with unresectable melanoma...
news
Amgen reacquires product rights to 3 products from GSK
15 December 2015 | By Victoria White
Amgen has entered into a definitive agreement with GSK to reacquire all of its remaining rights to Prolia (denosumab), XGEVA (denosumab) and Vectibix (panitumumab) in 48 countries...
news
Amgen presents new data on Kyprolis in multiple myeloma
7 December 2015 | By Victoria White
The data showed Kyprolis in combination with dexamethasone significantly extended disease progression compared to bortezomib plus dexamethasone...
news
Amgen submits MAA for biosimilar ABP 501 to the EMA
4 December 2015 | By Victoria White
Amgen believes this submission is the first adalimumab biosimilar application submitted to the EMA and represents Amgen's first biosimilar to be submitted for approval in the EU...
news
Amgen submits Biologices License Application for biosimilar ABP 501 to the FDA
26 November 2015 | By Victoria White
ABP 501 is a biosimilar candidate to AbbVie’s Humira (adalimumab), an anti-TNF-α monoclonal antibody, which is approved in many regions for the treatment of various inflammatory diseases...
news
EC approves Blincyto for acute lymphoblastic leukaemia
24 November 2015 | By Victoria White
Blincyto is the first bispecific CD19-directed CD3 T cell engager (BiTE) antibody construct approved in European Union...
news
EC grants marketing authorisation to Kyprolis in multiple myeloma
20 November 2015 | By Victoria White
The announcement makes Kyprolis (carfilzomib) the first irreversible proteasome inhibitor approved in the EU for use in combination treatment of patients with relapsed multiple myeloma.
news
NICE says ‘no’ to Amgen’s Repatha in draft guidance
18 November 2015 | By Victoria White
The NICE Committee felt the question whether Repatha (evolocumab) would reduce angina, heart attacks and strokes remains unanswered...
